Drug Profile
Trotabresib - Celgene Corporation
Alternative Names: BET inhibitor - Celgene Corporation; BMS-986378; CC 90010; QC5487; TROTA - Celgene CorporationLatest Information Update: 26 Nov 2023
Price :
$50
*
At a glance
- Originator Quanticel Pharmaceuticals
- Developer Bristol-Myers Squibb; Celgene Corporation
- Class Antineoplastics; Isoquinolines; Ketones; Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- Phase I/II Astrocytoma; Glioblastoma
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 18 Nov 2023 Northwestern University in collaboration with National Cancer Institute plans a phase I trial in HER2-positive breast cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (PO) in December 2023 (NCT06137651)
- 06 Feb 2023 Phase-II clinical trials in Solid tumours in USA (PO), prior to February 2023 (Bristol Myers Squibb pipeline, February 2023)
- 13 Jan 2023 Trotabresib is still in phase I trials for Solid tumours (Inoperable/Unresectable, Late-stage disease) in Spain, Japan, Italy and France (PO) (NCT03220347)